{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:16:46Z","timestamp":1794345406084,"version":"4.9.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring the safety and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing the relevant antigen, folate receptor-alpha. The trial incorporated skin prick and basophil activation tests (BAT) to select patients at lowest risk of allergic toxicity. Secondary objectives were exploration of anti-tumour activity, recommended Phase II dose, and pharmacokinetics. Dose escalation ranged from 70\u2009\u03bcg\u201312\u2009mg. The most common toxicity of MOv18 IgE is transient urticaria. A single patient experienced anaphylaxis, likely explained by detection of circulating basophils at baseline that could be activated by MOv18 IgE. The BAT assay was used to avoid enrolling further patients with reactive basophils. The safety profile is tolerable and maximum tolerated dose has not been reached, with evidence of anti-tumour activity observed in a patient with ovarian cancer. These results demonstrate the potential of IgE therapy for cancer.<\/jats:p>","DOI":"10.1038\/s41467-023-39679-9","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T06:02:19Z","timestamp":1690264939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-8491","authenticated-orcid":false,"given":"James","family":"Spicer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bristi","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-3123","authenticated-orcid":false,"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-1326","authenticated-orcid":false,"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-1716","authenticated-orcid":false,"given":"Rowan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"Veal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0706-6534","authenticated-orcid":false,"given":"Christopher J.","family":"Corrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9001-8754","authenticated-orcid":false,"given":"Mariangela","family":"Figini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-3587","authenticated-orcid":false,"given":"Silvana","family":"Canevari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Selkirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nintos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1197-2652","authenticated-orcid":false,"given":"Ionut-Gabriel","family":"Funingana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-8111","authenticated-orcid":false,"given":"Gary","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-688X","authenticated-orcid":false,"given":"Hannah J.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0387-1912","authenticated-orcid":false,"given":"Giulia","family":"Pellizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0699-6799","authenticated-orcid":false,"given":"Mano","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina M.","family":"Ilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atousa","family":"Khiabany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chara","family":"Stavraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitesh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-8910","authenticated-orcid":false,"given":"Sarah","family":"Pinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-4160","authenticated-orcid":false,"given":"Heather J.","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra H.","family":"Josephs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-7810","authenticated-orcid":false,"given":"Sophia N.","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"39679_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000479240","volume":"44","author":"A Kretschmer","year":"2017","unstructured":"Kretschmer, A., Schwanbeck, R., Valerius, T. & Rosner, T. Antibody isotypes for tumor immunotherapy. Transfus. Med. Hemother 44, 320\u2013326 (2017).","journal-title":"Transfus. Med. Hemother"},{"key":"39679_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00281-016-0565-1","volume":"38","author":"K Mukai","year":"2016","unstructured":"Mukai, K., Tsai, M., Starkl, P., Marichal, T. & Galli, S. J. IgE and mast cells in host defense against parasites and venoms. Semin. Immunopathol. 38, 581\u2013603 (2016).","journal-title":"Semin. Immunopathol."},{"key":"39679_CR3","doi-asserted-by":"crossref","unstructured":"Sutton, B.J., Davies, A.M., Bax, H.J. & Karagiannis, S.N. IgE antibodies: from structure to function and clinical translation. Antibodies (Basel) 8 (2019).","DOI":"10.3390\/antib8010019"},{"key":"39679_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/349243a0","volume":"349","author":"P Hagan","year":"1991","unstructured":"Hagan, P., Blumenthal, U. J., Dunn, D., Simpson, A. J. & Wilkins, H. A. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 349, 243\u2013245 (1991).","journal-title":"Nature"},{"key":"39679_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0972-4","volume":"20","author":"HC Hsiao","year":"2018","unstructured":"Hsiao, H. C., Fan, X., Jordan, R. E., Zhang, N. & An, Z. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo. Breast Cancer Res. 20, 43 (2018).","journal-title":"Breast Cancer Res."},{"key":"39679_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","volume":"33","author":"F Arce Vargas","year":"2018","unstructured":"Arce Vargas, F. et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33, 649\u2013663.e644 (2018).","journal-title":"Cancer Cell"},{"key":"39679_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","volume":"15","author":"GJ Weiner","year":"2015","unstructured":"Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15, 361\u2013370 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"39679_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1146\/annurev.immunol.21.120601.141103","volume":"21","author":"HJ Gould","year":"2003","unstructured":"Gould, H. J. et al. The biology of IgE and the basis of allergic disease. Annu. Rev. Immunol. 21, 579\u2013628 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"39679_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrd2909","volume":"11","author":"PM Hogarth","year":"2012","unstructured":"Hogarth, P. M. & Pietersz, G. A. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11, 311\u2013331 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"39679_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-007-0371-7","volume":"57","author":"SN Karagiannis","year":"2008","unstructured":"Karagiannis, S. N. et al. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol. Immunother. 57, 247\u2013263 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"39679_CR11","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.4049\/jimmunol.179.5.2832","volume":"179","author":"SN Karagiannis","year":"2007","unstructured":"Karagiannis, S. N. et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J. Immunol. 179, 2832\u20132843 (2007).","journal-title":"J. Immunol."},{"key":"39679_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/eji.200323185","volume":"33","author":"SN Karagiannis","year":"2003","unstructured":"Karagiannis, S. N. et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur. J. Immunol. 33, 1030\u20131040 (2003).","journal-title":"Eur. J. Immunol."},{"key":"39679_CR13","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5","volume":"29","author":"HJ Gould","year":"1999","unstructured":"Gould, H. J. et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur. J. Immunol. 29, 3527\u20133537 (1999).","journal-title":"Eur. J. Immunol."},{"key":"39679_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/0008-5472.CAN-16-1829","volume":"77","author":"DH Josephs","year":"2017","unstructured":"Josephs, D. H. et al. Anti-folate receptor-alpha IgE but not IgG recruits macrophages to attack tumors via TNFalpha\/MCP-1 signaling. Cancer Res. 77, 1127\u20131141 (2017).","journal-title":"Cancer Res."},{"key":"39679_CR15","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1111\/all.13455","volume":"73","author":"DH Josephs","year":"2018","unstructured":"Josephs, D. H. et al. An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE. Allergy 73, 2328\u20132341 (2018).","journal-title":"Allergy"},{"key":"39679_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00262-008-0607-1","volume":"58","author":"P Karagiannis","year":"2009","unstructured":"Karagiannis, P. et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2\/neu-positive tumour cells. Cancer Immunol. Immunother. 58, 915\u2013930 (2009).","journal-title":"Cancer Immunol. Immunother."},{"key":"39679_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ebiom.2019.03.080","volume":"43","author":"G Pellizzari","year":"2019","unstructured":"Pellizzari, G. et al. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. EBioMedicine 43, 67\u201381 (2019).","journal-title":"EBioMedicine"},{"key":"39679_CR18","doi-asserted-by":"publisher","first-page":"52553","DOI":"10.18632\/oncotarget.9651","volume":"7","author":"A Cheung","year":"2016","unstructured":"Cheung, A. et al. Targeting folate receptor alpha for cancer treatment. Oncotarget 7, 52553\u201352574 (2016).","journal-title":"Oncotarget"},{"key":"39679_CR19","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-18-0652","volume":"24","author":"A Cheung","year":"2018","unstructured":"Cheung, A. et al. Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer. Clin. Cancer Res. 24, 5098\u20135111 (2018).","journal-title":"Clin. Cancer Res."},{"key":"39679_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","volume":"151","author":"KN Moore","year":"2018","unstructured":"Moore, K. N. et al. Safety and activity findings from a phase Ib escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol. Oncol. 151, 46\u201352 (2018).","journal-title":"Gynecol. Oncol."},{"key":"39679_CR21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore, K. N. et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J. Clin. Oncol. 35, 1112\u20131118 (2017).","journal-title":"J. Clin. Oncol."},{"key":"39679_CR22","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1200\/JCO.2015.63.2596","volume":"34","author":"I Vergote","year":"2016","unstructured":"Vergote, I. et al. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J. Clin. Oncol. 34, 2271\u20132278 (2016).","journal-title":"J. Clin. Oncol."},{"key":"39679_CR23","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2712::AID-CNCR50>3.0.CO;2-B","volume":"80","author":"CF Molthoff","year":"1997","unstructured":"Molthoff, C. F. et al. Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 80, 2712\u20132720 (1997).","journal-title":"Cancer"},{"key":"39679_CR24","doi-asserted-by":"crossref","unstructured":"American Association for Cancer Research. FDA gives nod to mirvetuximab soravtansine. Cancer Discov. 13, 8 (2023).","DOI":"10.1158\/2159-8290.CD-NB2022-0075"},{"key":"39679_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1398-9995.2011.02728.x","volume":"67","author":"J Bousquet","year":"2012","unstructured":"Bousquet, J. et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy 67, 18\u201324 (2012).","journal-title":"Allergy"},{"key":"39679_CR26","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/all.14245","volume":"75","author":"HJ Bax","year":"2020","unstructured":"Bax, H. J. et al. Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate. Allergy 75, 2069\u20132073 (2020).","journal-title":"Allergy"},{"key":"39679_CR27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung, C. H. et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 358, 1109\u20131117 (2008).","journal-title":"N. Engl. J. Med."},{"key":"39679_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/cea.12326","volume":"44","author":"A Gonzalez-Quintela","year":"2014","unstructured":"Gonzalez-Quintela, A. et al. IgE antibodies to alpha-gal in the general adult population: relationship with tick bites, atopy, and cat ownership. Clin. Exp. Allergy 44, 1061\u20131068 (2014).","journal-title":"Clin. Exp. Allergy"},{"key":"39679_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"39679_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin, G. J. et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int. J. Gynecol. Cancer 21, 419\u2013423 (2011).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"39679_CR31","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1158\/0008-5472.CAN-17-0428","volume":"77","author":"SN Karagiannis","year":"2017","unstructured":"Karagiannis, S. N., Josephs, D. H., Bax, H. J. & Spicer, J. F. Therapeutic IgE antibodies: harnessing a macrophage-mediated immune surveillance mechanism against cancer. Cancer Res. 77, 2779\u20132783 (2017).","journal-title":"Cancer Res."},{"key":"39679_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jaci.2016.04.056","volume":"139","author":"MG Lawrence","year":"2017","unstructured":"Lawrence, M. G. et al. Half-life of IgE in serum and skin: consequences for anti-IgE therapy in patients with allergic disease. J. Allergy Clin. Immunol. 139, 422\u2013428.e424 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"39679_CR33","doi-asserted-by":"crossref","unstructured":"Nakamura, M. et al. IgE activates monocytes from cancer patients to acquire a pro-inflammatory phenotype. Cancers (Basel) 12 (2020).","DOI":"10.3390\/cancers12113376"},{"key":"39679_CR34","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3389\/fimmu.2017.01838","volume":"8","author":"D Soulat","year":"2017","unstructured":"Soulat, D. & Bogdan, C. Function of macrophage and parasite phosphatases in Leishmaniasis. Front. Immunol. 8, 1838 (2017).","journal-title":"Front. Immunol."},{"key":"39679_CR35","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1126\/science.8009216","volume":"264","author":"M Capron","year":"1994","unstructured":"Capron, M. & Capron, A. Immunoglobulin E and effector cells in schistosomiasis. Science 264, 1876\u20131877 (1994).","journal-title":"Science"},{"key":"39679_CR36","doi-asserted-by":"publisher","first-page":"e1593811","DOI":"10.1080\/2162402X.2019.1593811","volume":"8","author":"M Nakamura","year":"2019","unstructured":"Nakamura, M. et al. Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. Oncoimmunology 8, e1593811 (2019).","journal-title":"Oncoimmunology"},{"key":"39679_CR37","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/j.1365-2222.2011.03770.x","volume":"41","author":"SM Rudman","year":"2011","unstructured":"Rudman, S. M. et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of Fc\u03b5RI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin. Exp. Allergy 41, 1400\u20131413 (2011).","journal-title":"Clin. Exp. Allergy"},{"key":"39679_CR38","doi-asserted-by":"crossref","unstructured":"Passia, E. & Jandus, P. Using baseline and peak serum tryptase levels to diagnose anaphylaxis: a review. Clin. Rev. Allergy Immunol. 58, 366\u2013376 (2020).","DOI":"10.1007\/s12016-020-08777-7"},{"key":"39679_CR39","doi-asserted-by":"publisher","first-page":"1685349","DOI":"10.1080\/19420862.2019.1685349","volume":"12","author":"IP Williams","year":"2020","unstructured":"Williams, I. P. et al. In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. MAbs 12, 1685349 (2020).","journal-title":"MAbs"},{"key":"39679_CR40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","volume":"338","author":"N Parker","year":"2005","unstructured":"Parker, N. et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284\u2013293 (2005).","journal-title":"Anal. Biochem."},{"key":"39679_CR41","first-page":"3396","volume":"52","author":"SD Weitman","year":"1992","unstructured":"Weitman, S. D. et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52, 3396\u20133401 (1992).","journal-title":"Cancer Res."},{"key":"39679_CR42","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1158\/1078-0432.CCR-15-2640","volume":"22","author":"CE Hoogstins","year":"2016","unstructured":"Hoogstins, C. E. et al. A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer. Clin. Cancer Res. 22, 2929\u20132938 (2016).","journal-title":"Clin. Cancer Res."},{"key":"39679_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0156-0","volume":"8","author":"DJ O\u2019Shannessy","year":"2015","unstructured":"O\u2019Shannessy, D. J., Somers, E. B., Wang, L. C., Wang, H. & Hsu, R. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. J. Ovarian Res. 8, 29 (2015).","journal-title":"J. Ovarian Res."},{"key":"39679_CR44","doi-asserted-by":"crossref","unstructured":"Scaranti, M., Cojocaru, E., Banerjee, S. & Banerji, U. Exploiting the folate receptor alpha in oncology. Nat. Rev. Clin. Oncol. 17, 349\u2013359 (2020).","DOI":"10.1038\/s41571-020-0339-5"},{"key":"39679_CR45","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.19.00508","volume":"37","author":"LE Kandalaft","year":"2019","unstructured":"Kandalaft, L. E., Odunsi, K. & Coukos, G. Immunotherapy in ovarian cancer: are we there yet? J. Clin. Oncol. 37, 2460\u20132471 (2019).","journal-title":"J. Clin. Oncol."},{"key":"39679_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/hyb.2007.0512","volume":"26","author":"AE Smith","year":"2007","unstructured":"Smith, A. E. et al. A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues. Hybrid. (Larchmt.) 26, 281\u2013288 (2007).","journal-title":"Hybrid. (Larchmt.)"},{"key":"39679_CR47","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon, R. et al. Accelerated titration designs for phase I clinical trials in oncology. J. Natl Cancer Inst. 89, 1138\u20131147 (1997).","journal-title":"J. Natl Cancer Inst."},{"key":"39679_CR48","doi-asserted-by":"crossref","unstructured":"Bax, H. J. et al. Basophils from cancer patients respond to immune stimuli and predict clinical outcome. Cells 9 (2020).","DOI":"10.3390\/cells9071631"},{"key":"39679_CR49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.iac.2014.09.010","volume":"35","author":"KW Williams","year":"2015","unstructured":"Williams, K. W. & Sharma, H. P. Anaphylaxis and urticaria. Immunol. Allergy Clin. North Am. 35, 199\u2013219 (2015).","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"39679_CR50","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4161\/mabs.27029","volume":"6","author":"DH Josephs","year":"2014","unstructured":"Josephs, D. H., Spicer, J. F., Karagiannis, P., Gould, H. J. & Karagiannis, S. N. IgE immunotherapy: a novel concept with promise for the treatment of cancer. MAbs 6, 54\u201372 (2014).","journal-title":"MAbs"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39679-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39679-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39679-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T06:03:44Z","timestamp":1690265024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39679-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39679"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-39679-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"2 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. and S.K. are co-founders of Epsilogen Ltd. H.B. is presently employed, and J.C. formerly employed, through a fund from Epsilogen Ltd. S.K., H.B., H.G., D.J, G.P. and J.S. hold patents on anti-tumour IgE antibodies. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4180"}}